Business Context and Reporting Period
Company: Moderna, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2022
Reporting Period: Fiscal year ended December 31, 2021
Context: This filing accompanies a press release issued in connection with the Company's presentation at the 40th Annual J.P. Morgan Healthcare Conference, providing preliminary unaudited financial information.
Key Financial Metrics
- Product Sales (Unaudited): Approximately $17.5 billion for the fiscal year ended December 31, 2021, derived from sales of the COVID-19 vaccine.
- Dose Delivery: Approximately 807 million doses delivered worldwide (including both 50 µg and 100 µg/dose presentations).
- Equivalent Dose Volume: Approximately 790 million doses at the 100 µg/dose standard.
- Other Metrics: The filing text does not provide clear values for net profit, cash flow, operating margins, debt levels, or liquidity positions.
Material Changes
The filing text does not provide comparative data for the prior period (2020) or specific year-over-year percentage changes. It solely reports the absolute preliminary figures for the 2021 fiscal year.
Guidance, Outlook, and Risks
- Data Status: All financial information presented is unaudited and preliminary.
- Audit Contingency: The audit of the financial statements for the year ended December 31, 2021, is ongoing. The filing explicitly states that the audit could result in changes to the reported information.
- Legal Disclaimer: Information in Items 2.02 and 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the final audited revenue figure once the 2021 annual report (Form 10-K) is filed, as the $17.5 billion figure is preliminary.
- Confirm the final breakdown of dose volumes and pricing per dose to validate the revenue calculation.
- Review the upcoming Form 10-K for missing critical metrics such as net income, cash flow from operations, and balance sheet liquidity.
- Monitor for any restatements or adjustments resulting from the ongoing audit process.
